DailyMed lists Structured Product Labeling version 1 for the reviewed Afamelanotide label family with a published date of 2019-12-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 12 for the reviewed Pramlintide label family with a published date of 2019-12-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 11 for the reviewed Lixisenatide label family with a published date of 2019-12-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 10 for the reviewed Lixisenatide label family with a published date of 2019-12-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 9 for the reviewed Lixisenatide label family with a published date of 2019-12-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2019-25850, attributed to FDA and its parent HHS department, on 2019-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
DailyMed lists Structured Product Labeling version 6 for the reviewed Abaloparatide label family with a published date of 2019-11-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 8 for the reviewed Lixisenatide label family with a published date of 2019-11-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 207104 with status AP dated 2019-11-15, and names daptomycin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 4 for the reviewed Plecanatide label family with a published date of 2019-11-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 3 for the reviewed Plecanatide label family with a published date of 2019-11-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 1 for the reviewed Tesamorelin label family with a published date of 2019-11-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 210031 with status AP dated 2019-10-23, and names bivalirudin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 210797 with status AP dated 2019-10-08, and names afamelanotide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 211939 with status AP dated 2019-10-04, and names teriparatide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 213051 with status AP dated 2019-09-20, and names semaglutide among the application record's active ingredients.
The Federal Register published notice 2019-20108, attributed to FDA and its parent HHS department, on 2019-09-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Plecanatide.
The official Drugs@FDA dataset lists original submission 1 for NDA 212097 with status AP dated 2019-09-10, and names glucagon among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209422 with status AP dated 2019-09-09, and names carfilzomib among the application record's active ingredients.
The Federal Register published notice 2019-19347, attributed to FDA and its parent HHS department, on 2019-09-09. Its official title is “Determination That CALCIMAR (calcitonin salmon) Injection, 200 International Units Per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.
The Federal Register published notice 2019-18932, attributed to FDA and its parent HHS department, on 2019-09-03. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.
DailyMed lists Structured Product Labeling version 2 for the reviewed Ziconotide label family with a published date of 2019-08-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212022 with status AP dated 2019-08-22, and names daptomycin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 2 for the reviewed Plecanatide label family with a published date of 2019-07-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 211215 with status AP dated 2019-07-25, and names bivalirudin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 210134 with status AP dated 2019-07-24, and names glucagon among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 210118 with status AP dated 2019-07-15, and names icatibant acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212667 with status AP dated 2019-07-12, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212513 with status AP dated 2019-06-26, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211961 with status AP dated 2019-06-24, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 210557 with status AP dated 2019-06-21, and names bremelanotide acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 1 for the reviewed Plecanatide label family with a published date of 2019-06-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 208357 with status AP dated 2019-06-06, and names desmopressin acetate among the application record's active ingredients.
The Federal Register published notice 2019-11243, attributed to FDA and its parent HHS department, on 2019-05-30. Its official title is “Determination That LUPRON (Leuprolide Acetate) Injection, 1 Milligram/0.2 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
The Federal Register published notice 2019-10165, attributed to FDA and its parent HHS department, on 2019-05-16. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
The Federal Register published notice 2019-09007, attributed to FDA and its parent HHS department, on 2019-05-03. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 208375 with status AP dated 2019-05-01, and names daptomycin among the application record's active ingredients.
The Federal Register published notice 2019-06385, attributed to FDA and its parent HHS department, on 2019-04-02. Its official title is “Post-Marketing Pediatric-Focused Product Safety Reviews; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 204361 with status AP dated 2019-03-14, and names eptifibatide among the application record's active ingredients.
The Federal Register published rule 2019-04226, attributed to FDA and its parent HHS department, on 2019-03-13. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 204362 with status AP dated 2019-03-11, and names eptifibatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 7 for the reviewed Lixisenatide label family with a published date of 2019-03-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2019-03810, attributed to FDA and its parent HHS department, on 2019-03-04. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.
The Federal Register published notice 2019-03129, attributed to FDA and its parent HHS department, on 2019-02-25. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091374 with status AP dated 2019-02-14, and names desmopressin acetate among the application record's active ingredients.
The Federal Register published notice 2019-02146, attributed to FDA and its parent HHS department, on 2019-02-13. Its official title is “Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 210371 with status AP dated 2019-01-28, and names desmopressin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209864 with status AP dated 2019-01-25, and names eptifibatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 31 for the reviewed Dulaglutide label family with a published date of 2019-01-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.